Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
118.39
-1.07 (-0.90%)
Jan 17, 2025, 4:00 PM EST - Market closed
Revvity Revenue
Revvity had revenue of $684.05M in the quarter ending September 29, 2024, with 1.98% growth. This brings the company's revenue in the last twelve months to $2.72B, down -2.66% year-over-year. In the year 2023, Revvity had annual revenue of $2.75B, down -16.95%.
Revenue (ttm)
$2.72B
Revenue Growth
-2.66%
P/S Ratio
5.36
Revenue / Employee
$236,657
Employees
11,500
Market Cap
14.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
| Dec 29, 2019 | 2.88B | 105.68M | 3.80% |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
| Dec 28, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
RVTY News
- 7 days ago - Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing - Business Wire
- 8 days ago - Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance - Business Wire
- 10 days ago - Revvity Announces FDA Clearance for First Automated Free Testosterone Test - Business Wire
- 4 weeks ago - Revvity to Present at J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Safe Biopharma: Revvity's Recurring Revenues And Diagnostics - Seeking Alpha
- 5 weeks ago - Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst - Benzinga
- 2 months ago - Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK - Business Wire
- 2 months ago - Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells - Business Wire